吸煙與帕金森病嗅覺(jué)障礙

曹明 陳彪

·專(zhuān)題綜述·

吸煙與帕金森病嗅覺(jué)障礙

曹明 陳彪

帕金森病是臨床常見(jiàn)的神經(jīng)變性病，根據(jù)臨床癥狀可以分為運(yùn)動(dòng)癥狀和非運(yùn)動(dòng)癥狀，嗅覺(jué)障礙作為帕金森病最常見(jiàn)的非運(yùn)動(dòng)癥狀越來(lái)越受到重視。既往研究顯示，尼古丁可能降低帕金森病發(fā)病風(fēng)險(xiǎn)，而有吸煙史的帕金森病患者嗅覺(jué)障礙輕微，因此吸煙可能通過(guò)嗅覺(jué)系統(tǒng)對(duì)帕金森病產(chǎn)生保護(hù)作用。吸煙對(duì)帕金森病患者嗅覺(jué)功能的影響可能有助于我們更全面地了解帕金森病發(fā)病過(guò)程。

吸煙；帕金森病；嗅覺(jué)障礙；綜述

This study was supported by the National High Technology Research and Development Program of China(863 Program,No.2012AA02A514).

帕金森病（PD）是一種漸進(jìn)性神經(jīng)變性病，主要病理改變?yōu)榛咨窠?jīng)節(jié)黑質(zhì)多巴胺能神經(jīng)元缺失。帕金森病臨床癥狀分為運(yùn)動(dòng)癥狀和非運(yùn)動(dòng)癥狀（NMS），前者表現(xiàn)為靜止性震顫，肌強(qiáng)直，少動(dòng)和姿勢(shì)步態(tài)異常；后者包括嗅覺(jué)減退，自主神經(jīng)功能紊亂，睡眠障礙，認(rèn)知功能障礙等［1］。在上述非運(yùn)動(dòng)癥狀中，嗅覺(jué)減退可以出現(xiàn)在帕金森病臨床前期，有研究顯示，在發(fā)展為帕金森病的前4年即可出現(xiàn)顯著的嗅覺(jué)減退［2］，故嗅覺(jué)障礙可能是帕金森病臨床早期診斷的標(biāo)記。此為早期預(yù)測(cè)帕金森病的可能性提供依據(jù)。Braak研究團(tuán)隊(duì)曾經(jīng)提出帕金森病病理發(fā)展過(guò)程最先由鼻黏膜和胃腸系統(tǒng)開(kāi)始，即神經(jīng)毒素可能通過(guò)上述兩個(gè)系統(tǒng)由外環(huán)境直接進(jìn)入內(nèi)環(huán)境，引起嗅覺(jué)障礙和以便秘為主的胃腸功能障礙［3?4］。因此，研究帕金森病非運(yùn)動(dòng)癥狀發(fā)生、發(fā)展機(jī)制有助于了解基因與環(huán)境如何共同作用引起帕金森病的過(guò)程［5］，這也是目前越來(lái)越多的研究關(guān)注環(huán)境因素相關(guān)帕金森病非運(yùn)動(dòng)癥狀的原因。與帕金森病相關(guān)的環(huán)境和生活習(xí)慣因素眾多，有多項(xiàng)研究顯示，吸煙可以降低帕金森病發(fā)病風(fēng)險(xiǎn)［6?7］，但目前對(duì)帕金森病嗅覺(jué)障礙與吸煙保護(hù)作用之間的關(guān)系研究甚少。

一、嗅覺(jué)障礙與帕金森病

帕金森病嗅覺(jué)障礙于20世紀(jì)70年代由Ansari和Johnson［8］通過(guò)對(duì)22例帕金森病患者進(jìn)行研究后首次提出，此后Doty等［9］采用美國(guó)賓夕法尼亞大學(xué)嗅覺(jué)識(shí)別測(cè)驗(yàn)（UPSIT）進(jìn)一步證實(shí)約75%的帕金森病患者存在嗅覺(jué)察覺(jué)力損害，而90%的帕金森病患者存在嗅覺(jué)識(shí)別力損害。并且，帕金森病患者的這種嗅覺(jué)障礙與疾病進(jìn)展和嚴(yán)重程度無(wú)關(guān)聯(lián)性，也不隨抗帕金森病藥物的使用而改善［10］。多數(shù)研究通過(guò)對(duì)帕金森病亞型（靜止性震顫為主型，肌強(qiáng)直為主型及其他型）分析顯示，帕金森病各亞型之間嗅覺(jué)障礙并無(wú)顯著差異［11?12］。Hawkes等［3］和Duda［13］發(fā)現(xiàn)，α?突觸核蛋白（α?Syn）相關(guān)病理改變最早出現(xiàn)于嗅球處，由此提出假說(shuō)即帕金森病嗅覺(jué)障礙是這種病理過(guò)程逐漸向腦內(nèi)進(jìn)展的過(guò)程［3］。當(dāng)然，有研究顯示，這種嗅覺(jué)減退可能是由于嗅球處出現(xiàn)病理性損傷，嗅球內(nèi)神經(jīng)元減少，嗅球旁多巴胺能神經(jīng)元代償性增多導(dǎo)致多巴胺能神經(jīng)遞質(zhì)增多，而這種神經(jīng)遞質(zhì)阻礙嗅覺(jué)神經(jīng)沖動(dòng)傳遞，從而引起嗅覺(jué)減退［13?14］。盡管嗅覺(jué)障礙的發(fā)生機(jī)制尚未闡明，目前研究普遍認(rèn)為，嗅覺(jué)減退是發(fā)生在帕金森病運(yùn)動(dòng)癥狀前的非運(yùn)動(dòng)癥狀，且國(guó)際運(yùn)動(dòng)障礙學(xué)會(huì)（MDS）從2015年開(kāi)始將嗅覺(jué)減退納入帕金森病支持診斷標(biāo)準(zhǔn)，突出嗅覺(jué)減退對(duì)帕金森病診斷的重要性［15］。

二、吸煙與帕金森病

據(jù)統(tǒng)計(jì)，有超過(guò)60項(xiàng)流行病學(xué)調(diào)查研究均提示吸煙可以降低帕金森病發(fā)病風(fēng)險(xiǎn)［16?17］。其中一項(xiàng)納入300×103例受試者的流行病學(xué)調(diào)查研究顯示，在具有相同吸煙強(qiáng)度的人群中，煙齡與帕金森病發(fā)病風(fēng)險(xiǎn)呈負(fù)相關(guān)，且煙齡越久、帕金森病發(fā)病風(fēng)險(xiǎn)降低越明顯，但在相同煙齡人群中，日吸煙量與帕金森病發(fā)病風(fēng)險(xiǎn)無(wú)關(guān)聯(lián)性［18］。不可否認(rèn)，吸煙給人體帶來(lái)很多負(fù)面影響，增加心腦血管病和肺部惡性腫瘤等的發(fā)病風(fēng)險(xiǎn)，但是由于上述諸多流行病學(xué)研究提示吸煙可能具有神經(jīng)保護(hù)作用，這為隨后的相關(guān)機(jī)制研究提供研究背景。現(xiàn)有研究主要認(rèn)為尼古丁可能是神經(jīng)保護(hù)和降低帕金森病發(fā)病風(fēng)險(xiǎn)的重要因素［19］。Morens等［20］曾試圖解釋尼古丁對(duì)帕金森病的保護(hù)機(jī)制，即尼古丁可以刺激多巴胺能神經(jīng)遞質(zhì)釋放，通過(guò)一氧化碳阻止自由基損傷黑質(zhì)神經(jīng)元，同時(shí)抑制單胺氧化酶B（MAO?B）或通過(guò)競(jìng)爭(zhēng)性抑制神經(jīng)毒素以保護(hù)神經(jīng)元。在動(dòng)物模型中也可以觀(guān)察到尼古丁減緩黑質(zhì)紋狀體的損害進(jìn)展［21］，但在針對(duì)帕金森病患者的臨床實(shí)驗(yàn)中，尼古丁皮貼或口香糖均無(wú)法緩解帕金森病癥狀，因此尼古丁也許并不能單獨(dú)發(fā)揮神經(jīng)保護(hù)作用［21?23］。縱向研究顯示，吸煙的帕金森病患者與非吸煙的帕金森病患者在運(yùn)動(dòng)癥狀進(jìn)展與病死率方面無(wú)顯著差異［24?27］，提示對(duì)于明確診斷的帕金森病患者，吸煙并不能起保護(hù)作用，但是有研究顯示，吸煙人群帕金森病發(fā)病年齡高于非吸煙人群［28］。因此認(rèn)為，尼古丁對(duì)帕金森病患者的影響可能在發(fā)病前即已存在，并且是緩慢影響過(guò)程，這也可能是明確診斷為帕金森病的患者再次使用尼古丁制劑治療效果不明顯的原因［29］。

三、吸煙對(duì)帕金森病患者嗅覺(jué)的影響

盡管針對(duì)帕金森病患者嗅覺(jué)障礙的相關(guān)研究已進(jìn)行近40年，但關(guān)于吸煙對(duì)帕金森病患者嗅覺(jué)影響的研究卻較少。帕金森病患者UPSIT評(píng)分較低。但近期一項(xiàng)研究顯示，有吸煙史的帕金森病患者UPSIT評(píng)分優(yōu)于非吸煙的帕金森病患者，而在正常對(duì)照組中卻未觀(guān)察到類(lèi)似現(xiàn)象，研究者猜測(cè)吸煙可能對(duì)帕金森病患者的嗅覺(jué)功能具有保護(hù)作用［29］。另一項(xiàng)研究也發(fā)現(xiàn)吸煙人群中帕金森病患者與正常對(duì)照者UPSIT評(píng)分無(wú)顯著差異，而帕金森病患者中吸煙人群UPSIT評(píng)分顯著優(yōu)于非吸煙和既往吸煙者［30］。這一結(jié)果并不受吸煙習(xí)慣如是否戒煙、戒煙時(shí)間長(zhǎng)短、吸煙量和帕金森病藥物治療的影響。大多數(shù)研究顯示，吸煙可引起正常人群嗅覺(jué)障礙［31?32］，Moccia等［33］的橫斷面研究顯示，正常人群中吸煙者UPSIT評(píng)分顯著低于非吸煙者，但是這一現(xiàn)象并未出現(xiàn)在帕金森病患者中，因此他們認(rèn)為，帕金森病患者嗅覺(jué)障礙可能受帕金森病與吸煙的共同影響。另有針對(duì)毒氣引起嗅覺(jué)障礙的研究顯示，非吸煙者出現(xiàn)嗅覺(jué)障礙的風(fēng)險(xiǎn)相對(duì)增加，盡管其發(fā)生機(jī)制尚不清楚，但吸煙可能對(duì)嗅覺(jué)功能存在某種保護(hù)作用［34?35］。基于Braak等［36］對(duì)帕金森病病理進(jìn)展過(guò)程的解釋?zhuān)鼰熃档团两鹕“l(fā)病風(fēng)險(xiǎn)可能是由于吸煙損害嗅黏膜，導(dǎo)致外環(huán)境毒素較少通過(guò)嗅覺(jué)系統(tǒng)進(jìn)入中樞。有研究顯示，尼古丁成分可影響膽堿能系統(tǒng)，而膽堿能系統(tǒng)能夠輔助嗅覺(jué)的氣味察覺(jué)功能［37?39］。其他研究則提出尼古丁可以增加嗅球處血流量從而減少自由基對(duì)嗅球的損害［40］。Rothermel等［41］認(rèn)為，尼古丁可以上調(diào)或直接刺激基底前腦突觸前尼古丁受體，而此區(qū)域與嗅覺(jué)有關(guān)，推測(cè)尼古丁可以使受損嗅皮質(zhì)功能增強(qiáng)。在阿爾茨海默病（AD）動(dòng)物模型研究中發(fā)現(xiàn)，尼古丁可以減少嗅束淀粉樣變性［42］。將膽堿能受體阻斷劑注入小鼠嗅球，嗅覺(jué)辨別功能增強(qiáng)，而阻斷嗅球處尼古丁受體時(shí)，嗅覺(jué)功能減退［10］。但Bryant等［43］認(rèn)為，尼古丁并未直接通過(guò)尼古丁?膽堿能受體作用于嗅覺(jué)系統(tǒng)，而是通過(guò)cAMP介導(dǎo)的嗅覺(jué)感受器通路激活嗅覺(jué)神經(jīng)元。因此，對(duì)于尼古丁如何影響嗅覺(jué)功能的作用機(jī)制尚待進(jìn)一步研究。流行病學(xué)研究顯示，戒煙困難的人群相對(duì)于戒煙容易的人群，帕金森病發(fā)病風(fēng)險(xiǎn)降低約31%［44］。研究者認(rèn)為這種吸煙行為的改變可能是并列于其他非運(yùn)動(dòng)癥狀如嗅覺(jué)減退、便秘、睡眠障礙等［45］的另一種帕金森病臨床前期非運(yùn)動(dòng)癥狀。但是吸煙行為中仍有許多不確定因素，如吸煙強(qiáng)度不能僅考慮數(shù)包或數(shù)只香煙而忽略每種香煙的尼古丁含量，開(kāi)始吸煙年齡、煙齡、戒煙年齡和戒斷時(shí)間，研究對(duì)象是否攜帶帕金森病風(fēng)險(xiǎn)基因，吸煙人群所占研究隊(duì)列中的比例等因素，均有可能影響研究結(jié)果。因此，尚不能確定吸煙對(duì)帕金森病的嗅覺(jué)功能具有保護(hù)作用。

四、結(jié)語(yǔ)

上述研究闡述吸煙與帕金森病嗅覺(jué)障礙的關(guān)系。嗅覺(jué)障礙作為帕金森病較為明確的臨床前期癥狀，受多種外環(huán)境因素的影響，而吸煙作為流行病學(xué)研究發(fā)現(xiàn)的可能降低帕金森病發(fā)病風(fēng)險(xiǎn)的因素之一，很可能通過(guò)嗅覺(jué)系統(tǒng)降低帕金森病發(fā)病風(fēng)險(xiǎn)。因此在帕金森病患者中，吸煙與嗅覺(jué)系統(tǒng)的相互作用也越來(lái)越受到關(guān)注。通過(guò)吸煙與嗅覺(jué)和帕金森病的相關(guān)研究，可以更全面地了解帕金森病發(fā)病過(guò)程，嗅覺(jué)障礙發(fā)生機(jī)制以及如何利用香煙中的成分對(duì)帕金森病臨床前期進(jìn)行保護(hù)性干預(yù)。

［1］Liu SY,Chan P.Epidemiology of Parkinson's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi,2016,16:98?101.［劉疏影,陳彪.帕金森病流行現(xiàn)狀.中國(guó)現(xiàn)代神經(jīng)疾病雜志, 2016,16:98?101.］

［2］Ross GW,Petrovitch H,Abbott RD,Tanner CM,Popper J, Masaki K,Launer L,White LR.Association of olfactory dysfunction with risk for future Parkinson's disease.Ann Neurol,2008,63:167?173.

［3］Hawkes CH,Del Tredici K,Braak H.Parkinson's disease:a dual?hit hypothesis.Neuropathol Appl Neurobiol,2007,33:599?614.

［4］Hawkes CH,Del Tredici K,Braak H.Parkinson's disease:the dual hit theory revisited.Ann NY Acad Sci,2009,1170:615?622.

［5］Chen H,Burton EA,Ross GW,Huang X,Savica R,Abbott RD, Ascherio A,Caviness JN,Gao X,Gray KA,Hong JS,Kamel F, Jennings D,Kirshner A,Lawler C,Liu R,Miller GW, Nussbaum R,Peddada SD,Rick AC,Ritz B,Siderowf AD, Tanner CM,Tr?ster AI,Zhang J.Research on the premotor symptoms of Parkinson's disease:clinical and etiological implications.Environ Health Perspect,2013,121:1245?1252.

［6］Katotomichelakis M,Balatsouras D,Tripsianis G,Davris S, Maroudias N,Danielides V,Simopoulos C.The effect of smoking on the olfactory function.Rhinology,2005,45:273?280.

［7］Nicoletti A,Pugliese P,Nicoletti G,Arabia G,Annesi G,Mari MD,Lamberti P,Grasso L,Marconi R,Epifanio A,Morgante L, Cozzolino A,Barone P,Torchia G,Quattrone A,Zappia M. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case?control study.Mov Disord,2010,25:2387? 2394.

［8］Ansari KA,Johnson A.Olfactory function in patients with Parkinson's disease.J Chronic Dis,1975,28:493?497.

［9］Doty RL,Deems DA,Stellar S.Olfactory dysfunction in parkinsonism:a general deficit unrelated to neurologic signs, disease stage,or disease duration.Neurology,1988,8:1237?1244.

［10］Doty RL.Olfactory dysfunction in Parkinson disease.Nat Rev Neurol,2012,8:329?339.

［11］Lee HM,Koh SB.Many faces of Parkinson's disease:non?motor symptoms of Parkinson's disease.J Mov Disord,2015,8:92?97.

［12］Casjens S,Eckert A,Woitalla D,Ellrichmann G,Turewicz M, Stephan C,Eisenacher M,May C,Meyer HE,Brüning T,Pesch B.Diagnostic value of the impairment of olfaction in Parkinson's disease.PLoS One,2015,8:E64735.

［13］Duda JE.Olfactory system pathology as a model of Lewy neurodegenerative disease.J Neurol Sci,2013,289:49?54.

［14］Surmeier DJ,Sulzer D.The pathology roadmap in Parkinson disease.Prion,2013,7:85?91.

［15］Postuma RB,Berg D,Stern M,Poewe W,Olanow CW,Oertel W,Obeso J,Marek K,Litvan I,Lang AE,Halliday G,Goetz CG,Gasser T,Dubois B,Chan P,Bloem BR,Adler CH, Deuschl G.MDS clinical diagnostic criteria for Parkinson's disease.Mov Disord,2015,30:1591?1601.

［16］Kenborg L,Lassen CF,Ritz B,Andersen KK,Christensen J, Schernhammer ES,Hansen J,Wermuth L,Rod NH,Olsen JH. Lifestyle,family history,and risk of idiopathic Parkinson disease:a large Danish case?control study.Am J Epidemiol, 2015,181:808?816.

［17］Liu R,Guo X,Park Y,Huang X,Sinha R,Freedman ND, Hollenbeck AR,Blair A,Chen H.Caffeine intake,smoking, and risk of Parkinson disease in men and women.Am J Epidemiol,2012,175:1200?1207.

［18］Chen H,Huang X,Guo X,Mailman RB,Park Y,Kamel F, Umbach DM,Xu Q,Hollenbeck A,Schatzkin A,Blair A. Smoking duration,intensity,and risk of Parkinson disease. Neurology,2010,74:878?884.

［19］Greenbaum L,Rigbi A,Lipshtat N,Cilia R,Tesei S,Asselta R, Djaldetti R,Goldwurm S,Lerer B.Association of nicotine dependence susceptibility gene,CHRNA5,with Parkinson's disease age at onset:gene and smoking status interaction. Parkinsonism Relat Disord,2013,19:72?76.

［20］Morens DM,Grandinetti A,Reed D,White LR,Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?Neurology,1995,45:1041?1051.

［21］Quik M,Perez XA,Bordia T.Nicotine as a potential neuroprotective agent for Parkinson's disease.Mov Disord, 2012,27:947?957.

［22］Srinivasan R,Henley BM,Henderson BJ,Indersmitten T, Cohen BN,Kim CH,McKinney S,Deshpande P,Xiao C,Lester HA.Smoking?relevant nicotine concentration attenuates the unfolded protein response in dopaminergic neurons.J Neurosci, 2016,36:65?79.

［23］Quik M,Huang LZ,Parameswaran N,Bordia T,Campos C, Perez XA.Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol,2009,78:677?685.

［24］Alves G,Kurz M,Lie SA,Larsen JP.Cigarette smoking in Parkinson's disease:influence on disease progression.Mov Disord,2004,19:1087?1092.

［25］Kandinov B,Giladi N,Korczyn AD.The effect of cigarette smoking,tea,and coffee consumption on the progression of Parkinson's disease.Parkinsonism Relat Disord,2007,13:243?245.

［26］Elbaz A,Bower JH,Peterson BJ,Maraganore DM,McDonnell SK,Ahlskog JE,Schaid DJ,Rocca WA.Survival study of Parkinson disease in Olmsted County,Minnesota.Arch Neurol, 2003,60:91?96.

［27］Chen H,Zhang SM,Schwarzschild MA,Hernán MA,Ascherio A.Survival of Parkinson's disease patients in a large prospective cohort of male health professionals.Mov Disord, 2006,21:1002?1007.

［28］Breckenridge CB,Berry C,Chang ET,Sielken RL Jr,Mandel JS.Association between Parkinson's disease and cigarette smoking,rural living,well?water consumption,farming and pesticide use:systematic review and meta?analysis.PLoS One, 2016,11:E0151841.

［29］Lucassen EB,Sterling NW,Lee EY,Chen H,Lewis MM,Kong L,Huang X.History of smoking and olfaction in Parkinson's disease.Mov Disord,2014,29:1069?1074.

［30］Sharer JD,Leon?Sarmiento FE,Morley JF,Weintraub D,Doty RL.Olfactory dysfunction in Parkinson's disease:positive effect of cigarette smoking.Mov Disord,2015,30:859?862.

［31］Malaty J,Malaty IA.Smell and taste disorders in primary care. Am Fam Physician,2013,88:852?859.

［32］Hayes JE,Jinks AL.Evaluation of smoking on olfactory thresholds of phenyl ethyl alcohol and n?butanol.Physiol Behav,2012,107:177?180.

［33］Moccia M,Picillo M,Erro R,Vitale C,Amboni M,Palladino R, Cioffi DL,Barone P,Pellecchia MT.How does smoking affect olfaction in Parkinson's disease?J Neurol Sci,2013,340:215?217.

［34］Schwartz BS,Ford DP,Bolla KI,Agnew J,Rothman N, Bleecker ML.Solvent?associated decrements in olfactory function in paint manufacturing workers.Am J Ind Med, 1990,18:697?706.

［35］Schwartz BS,Doty RL,Monroe C,Frye R,Barker S.Olfactory function in chemical workers exposed to acrylate and methacrylate vapors.Am J Public Health,1989,79:613?618.

［36］Braak H,Del Tredici K,Bratzke H,Hamm?Clement J, Sandmann?Keil D,Rüb U.Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).J Neurol,2002,249(Suppl 3):1?5.

［37］Perez XA.Preclinical evidence for a role of the nicotinic cholinergic system in Parkinson's disease.Neuropsychol Rev, 2012,25:371?383.

［38］Mandairon N,Peace ST,Boudadi K,Boxhorn CE,Narla VA, Suffis SD,Cleland TA.Compensatory responses to age?related decline in odor quality acuity:cholinergic neuromodulation and olfactory enrichment.Neurobiol Aging,2012,32:2254?2265.

［39］Chambers RP,Call GB,Meyer D,Smith J,Techau JA,Pearman K,Buhlman LM.Nicotine increases lifespan and rescues olfactory and motor deficits in a Drosophila model of Parkinson's disease.Behav Brain Res,2013,253:95?102.

［40］Shiba K,Machida T,Uchida S,Hotta H.Effects of nicotine on regional blood flow in the olfactory bulb in rats.Eur J Pharmacol,2006,546:148?151.

［41］Rothermel M,Carey RM,Puche A,Shipley MT,Wachowiak M. Cholinergic inputs from basal forebrain add an excitatory bias to odor coding in the olfactory bulb.J Neurosci,2014,34:4654?4664.

［42］Chouliaras L,Sierksma AS,Kenis G,Prickaerts J,Lemmens MA,Brasnjevic I,van Donkelaar EL,Martinez?Martinez P, Losen M,De Baets MH,Kholod N,van Leeuwen F,Hof PR, van Os J,Steinbusch HW,van den Hove DL,Rutten BP.Gene?environment interaction research and transgenic mouse models of Alzheimer's disease.Int J Alzheimers Dis,2010:ID859101.

［43］Bryant B,Xu J,Audige V,Lischka FW,Rawson NE.Cellular basis for the olfactory response to nicotine.ACS Chem Neurosci,2011,1:246?256.

［44］Ritz B,Lee PC,Lassen CF,Arah OA.Parkinson disease and smoking revisited:ease of quitting is an early sign of the disease.Neurology,2014,83:1396?1402.

［45］Ross GW,Abbott RD,Petrovitch H,Tanner CM,White LR.Pre?motor features of Parkinson's disease:the Honolulu?Asia Aging Study experience.Parkinsonism Relat Disord,2012,18(Suppl 1): 199?202.

Relationship between smoking and olfactory dysfunction in Parkinson's disease

CAO Ming,CHAN Piu
Department of Neurology,Xuanwu Hospital,Capital Medical University,Beijing 100053,China Corresponding author:CHAN Piu(Email:pbchan90@gmail.com)

Parkinson's disease(PD)is a common neurodegenerative disease.It is characterized by a combination of motor symptoms and non?motor symptoms(NMS)based on clinical symptoms.More and more attention has been drawn to olfactory dysfunction as an early NMS in PD.It is believed that nicotine in cigarettes may lower the risk of getting PD and people with smoking history may have lower risk of olfactory dysfunction.So smoking may have protective effect on PD.The effect of smoking on olfactory function in PD patients may lead us to have a better understanding of the pathogenesis of PD.

Smoking;Parkinson disease;Olfaction disorders;Review

2016?10?30）

10.3969/j.issn.1672?6731.2017.02.004

國(guó)家高技術(shù)研究發(fā)展計(jì)劃（863計(jì)劃）項(xiàng)目（項(xiàng)目編號(hào)：2012AA02A514）

100053北京，首都醫(yī)科大學(xué)宣武醫(yī)院神經(jīng)內(nèi)科

陳彪（Email：pbchan90@gmail.com）